Aspira Women's Health Inc. (AWHL)
Aspira Women’s Health develops blood-based diagnostic tests powered by AI to assess ovarian cancer risk and detect gynecologic disease in women. The company operates a CLIA-certified laboratory in Texas and sells its OvaSuite diagnostic portfolio—including OvaWatch and Ova1Plus tests—to healthcare systems, gynecologists, and surgical centers throughout the United States.
Laboratory and Testing Operations
Aspira Labs, Inc., the company’s CLIA laboratory, processes blood-based tests designed to stratify risk in women with adnexal masses or other gynecologic concerns. The diagnostic methodology uses AI-enhanced analysis of biomarkers to generate risk scores that help clinicians decide on next steps—conservative monitoring or surgical intervention. The company addresses a large market: approximately 1.2 million American women annually are diagnosed with adnexal masses, many requiring evaluation for ovarian cancer risk.
Revenue Model and Market Focus
The company generates revenue from laboratory test processing and interpretation fees paid by healthcare providers, patients, and insurers. It distributes through a direct sales force focused on large health systems and integrated delivery networks, supported by proprietary claims data analytics to identify high-opportunity accounts. Unlike volume-driven models, Aspira’s recent strategic shift emphasizes profitability per test and institutional partnerships over broad market saturation.
At a Glance
- Blood-based ovarian cancer risk assessment using AI-enhanced biomarker analysis
- CLIA laboratory operations based in Texas
- Revenue from test processing fees and reimbursement
- Primary customers: health systems, gynecology practices, surgical oncology centers
- Business model: profitable recurring relationships with large institutional buyers
- Market opportunity: 1.2 million women diagnosed with adnexal masses annually in the U.S.